To include your compound in the COVID-19 Resource Center, submit it here.

Ardelyx discontinues development of hyperkalemia candidate RDX7675

In a pipeline update Nov. 21, Ardelyx Inc. (NASDAQ:ARDX) said it will discontinue development of

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE